The insulin-like growth factor (IGF) signaling axis has been implicated in promoting cancer progression in several tumor types including breast cancer [27–29], and in breast cancer resistance to estrogen and HER2 receptor inhibition [27, 30–32]. This evidence concerns the gene IGF1 and breast cancer.